Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
about
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapyData-independent proteomic screen identifies novel tamoxifen agonist that mediates drug resistanceA Review of the Clinical Implications of Breast Cancer BiologyUrokinase receptor and resistance to targeted anticancer agentsA ranking method for the concurrent learning of compounds with various activity profiles.A genome-wide association study identifies a genetic variant in the SIAH2 locus associated with hormonal receptor-positive breast cancer in JapaneseIdentification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer.S100β as a serum marker in endocrine resistant breast cancer.Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferationMathematical models of the transitions between endocrine therapy responsive and resistant states in breast cancer.IKKepsilon phosphorylation of estrogen receptor alpha Ser-167 and contribution to tamoxifen resistance in breast cancer.Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomesProlylcarboxypeptidase regulates proliferation, autophagy, and resistance to 4-hydroxytamoxifen-induced cytotoxicity in estrogen receptor-positive breast cancer cells.Overexpression of prostate tumor overexpressed 1 correlates with tumor progression and predicts poor prognosis in breast cancer.Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer.Evolutionary dynamics of carcinogenesis and why targeted therapy does not work.An induction of microRNA, miR-7 through estrogen treatment in breast carcinoma.RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response.Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro.The potential role of estrogen receptors and the SRC family as targets for the treatment of breast cancer.Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studiesDNA stabilization by the upregulation of estrogen signaling in BRCA gene mutation carriers.A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer.The pitfall of the transient, inconsistent anticancer capacity of antiestrogens and the mechanism of apparent antiestrogen resistanceA transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogenIsorhamnetin inhibits cell proliferation and induces apoptosis in breast cancer via Akt and mitogen‑activated protein kinase kinase signaling pathwaysBCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinibAndrogen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancerCritical roles for nitric oxide and ERK in the completion of prosurvival autophagy in 4OHTAM-treated estrogen receptor-positive breast cancer cells.Circulatory estrogen level protects against breast cancer in obese women.Molecular targeted therapies for breast cancer treatment.The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin.Tamoxifen resistance in breast cancer.Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer.ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization.Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer.Triple-negative breast cancer risk in women is defined by the defect of estrogen signaling: preventive and therapeutic implicationsPredicting Drug Combination Index and Simulating the Network-Regulation Dynamics by Mathematical Modeling of Drug-Targeted EGFR-ERK Signaling Pathway.Role of EGF/ERBB1 in the transcriptional regulation of the prolactin receptor independent of estrogen and prolactin in breast cancer cells.
P2860
Q21198871-B0A0F161-28A6-4104-80A4-6475E17B3D47Q24626049-4828E58E-1C65-4B5C-B2C1-E851EFA1F6DBQ26744288-01937DFF-5FD1-426A-B832-CEF8E76FCFF2Q26797385-17A6312D-4110-48B3-A6BA-571E5F83885CQ27902271-E343DEA5-5D18-4955-875A-EB1FE0D8CB4CQ28943445-3D669463-7F39-47BB-989B-F8059A7FBF84Q33423808-C4442ACF-A88C-4962-92AB-DF5C868732C8Q33556608-55FD5DED-A7B5-4764-9D3E-04B56C06E7BBQ33612070-E3A0AF8D-49D8-46BA-8695-987C7CCE34CDQ33656026-911170A8-85D1-4EE6-B8EA-EFF11EC67A16Q33662031-ACC7C947-E36F-49F6-A28D-C4F03D01BFDCQ33691211-E1BE1467-3D9B-44CD-A022-FF27BF552EFDQ33750907-CEF156CB-B439-44E1-9C9A-E8D7911A06C0Q33804529-3EA8AA8A-21AD-4B1A-8352-A4EBCB24C7EBQ33941574-3A4B40CA-D37B-478B-BE28-F18EE5AFCC34Q34005286-D86FDB48-1719-4C91-BBCF-C30E98DC729AQ34507441-D56FB9B4-28F2-4C1A-B8C2-6B6F2C68F50EQ34659897-21EAF6E5-AADA-46D3-98A0-7F4FF34A72D4Q34908885-634C9265-9F93-46AE-91F8-022055F855E0Q34982010-6BBC2F77-E727-4ABC-B451-EABB751CA770Q35016088-B2D6AC47-7429-4889-BD51-CA4B1119BBE5Q35633272-C9554351-6B32-44DB-BEEB-6FCB33291114Q35771300-5CFCA7CD-AC32-4C58-B0A3-E9AAB45B8F82Q35889618-961C8A22-3977-48E7-B9FA-AA4908D3741FQ35939435-34F21476-7CC9-4EC4-9890-BB16B5D5BAEBQ36059078-44A01D5D-FECF-4CD8-BA46-A5C32F18A420Q36224926-8A9D0FFD-4607-4973-8B0E-9EEB1904D45AQ36299102-B2C5511C-E592-44C9-90DB-E34A4985F512Q36568006-F6F5D6E9-5242-4552-A3A9-44CA0BA13B96Q36787062-B8BB02F5-5A3B-42D8-B0FA-6657391CA572Q36795622-AD0355EE-3AFC-493C-B229-134C386CD8C9Q36955065-EA3BF169-E694-4B1D-ACA8-FF36DA2F5EBEQ37036957-F2554138-1AE3-4355-B90C-A8519B6CC381Q37224555-45BBDBCE-AC1A-4D71-A8F8-CF1DCC44BE0DQ37254804-2FA173AA-6014-4A05-8939-830D144135DCQ37302065-23593D1D-A8C1-46DF-938F-458FD6D51E58Q37360234-A4F7CC4A-61D3-4B73-89B3-4A6BC6C6B9DDQ37525906-102F132B-B8E7-475E-BB7A-D78BB1D370A5Q37593264-559EAE58-F51C-45B5-9976-1BD3E8011532Q37662281-5A8F3D2E-C223-469E-AEFA-494A670868B5
P2860
Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Resistance to endocrine therap ...... th factor signaling crosstalk.
@ast
Resistance to endocrine therap ...... th factor signaling crosstalk.
@en
type
label
Resistance to endocrine therap ...... th factor signaling crosstalk.
@ast
Resistance to endocrine therap ...... th factor signaling crosstalk.
@en
prefLabel
Resistance to endocrine therap ...... th factor signaling crosstalk.
@ast
Resistance to endocrine therap ...... th factor signaling crosstalk.
@en
P356
P1476
Resistance to endocrine therap ...... th factor signaling crosstalk.
@en
P2093
Rachel Schiff
P304
P356
10.1677/ERC.1.01273
P478
13 Suppl 1
P577
2006-12-01T00:00:00Z